Related Experiment Video
Updated: Apr 5, 2026
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Pathogenic mechanisms and the prospect of gene therapy for choroideremia
Ioannis S Dimopoulos1, Stephanie Chan1, Robert E MacLaren2
1University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, Alberta, Canada.
Introduction:
Choroideremia is a rare, X-linked disorder recognized by its specific ocular phenotype as a progressive degenerative retinopathy resulting in blindness. New therapeutic approaches, primarily based on genetic mechanisms, have emerged that aim to prevent the progressive vision loss.
Areas Covered:
This article will review the research that has progressed incrementally over the past two decades from mapping to gene discovery, uncovering the presumed mechanisms triggering the retinopathy to preclinical testing of potential therapies.
Expert Opinion:
While still in an evaluative phase, the introduction of gene replacement as a potential therapy has been greeted with great enthusiasm by patients, advocacy groups and the medical community.
Insights
Gene therapy offers a promising new approach to combat choroideremia, a rare X-linked retinopathy. Research is advancing towards preclinical testing to prevent vision loss from this degenerative eye disease.
Area of Science:
- Ophthalmology
- Genetics
- Retinal Degenerative Diseases
Background:
- Choroideremia is a rare, X-linked inherited condition causing progressive vision loss.
- The disease is characterized by a degenerative retinopathy leading to blindness.
- Emerging genetic therapies aim to halt the progression of vision loss.
Purpose of the Study:
- To review two decades of research on choroideremia.
- To cover gene mapping, discovery, and understanding of disease mechanisms.
- To discuss the preclinical testing of novel therapeutic strategies.
Main Methods:
- Literature review of choroideremia research over the past 20 years.
- Analysis of studies from gene mapping to preclinical therapy trials.
- Synthesis of information on disease mechanisms and therapeutic development.
Main Results:
- Significant progress has been made in understanding the genetic basis of choroideremia.
- Preclinical studies are evaluating the efficacy of gene replacement therapies.
- Research has elucidated the mechanisms underlying the retinopathy.
Conclusions:
- Gene replacement therapy shows potential for treating choroideremia.
- This therapeutic approach is highly anticipated by patients and the medical community.
- Current therapies are still in the evaluative phase but offer significant hope.
More Related Videos
05:09Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye
Published on: November 25, 2012
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
Related Concept Videos
00:59Gene Therapy
00:59Gene Therapy
01:29Microorganisms in Medicine and Therapeutics
00:49What is Genetic Engineering?
01:29Pharmacogenomics: Identification of New Drug Targets
01:22iPS Cell Differentiation